Current status of islet xenotransplantation by Park, CG et al.
- 1 -
CURRENT STATUS OF LIVER TRANSPLANTATION 
Thomas E. Starzl, M.D., Ph.D. 
Shunzaburo Iwatsuki, M.D. 
Byers W. Shaw, Jr., M.D. 
From the Department of Surgery, University of.Pittsburgh Health 
Center, University of Pittsburgh, Pittsburgh, Pennsylvania. 
Supported by research grants from the Veterans Administration; by 
project grant AM-29961 from the National 'Institutes of Health and 
by grant RR-00084 from the General Clinical Research Centers 
Program of the Division of Research Resources, National Insti-
tutes of Health. 
- 2 -
I would like to cover this morning the experience which we 
have had with liver transplantation and to try to indicate to- you 
where I think developments in this field will be going. There 
has been some interesting administrative movement in the United 
States which may have relevance to the objectives of workers in 
Europe and the Middle East. 
Liver transplantation has been considered to be an 
experimental undertaking and for that reason (and the consequent 
inability to fund these efforts) it has been difficult for 
centers other than the ones where I have worked to get started. 
However, the perception has grown in the last two or three years 
as resul ts have i mprov ed with the i ntroduc t i on of cyc lospor i ne 
that the procedure really is not experimental. There is in 
process in the Un i ted Sta tes an adm in i s tra t i ve cha in of even ts 
known as a Consensus aevelop~ent which will corne to completion in 
June 1983 and wh i ch will almost c erta i n ly 1 ead . to a government 
decision that liver transplantation is in fact therapeutic. 
When that time comes, we believe that a network of centers 
capable of providing liver transplantation will spring up in the 
United States almost overnight. We think that the number of 
centers will be 20 or 30. There are already several active 
groups and there are in training several other teams. The steps 
in making liver transplantation a widespread service are 
following somewhat the same format as the development of renal 
transplantation about 20 years ago in our country. 
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THE DIMENSIONS OF THE PROBLEM 
Data about the need for hepatic transplantation is being 
accumulated. It has become obvious that the numbers of potential 
candidates are far higher than anyone had realized. Until 
recently no one had taken a good look at this question, perhaps 
because it was perceived to be a non-issue, but my estimate is 
that at an equilibrium level the number of liver transplantations 
in the Unites States will be in the 5,000 per year range. Many 
of you know that this is about the number of renal 
transplantations in the United States per year. In our country, 
liver disease is the fourth most common cause of death. 
Although a significant proportion of these deaths are 
alcohol related, a surprising percent are free of the alcohol 
taint. Moreover, there is no reason to arbitrarily exclude 
patients with alcoholic cirrhosis from treatment. A number of 
years ago it was estimated that there might be as many as 5,000 
potential candidates for liver transplantation in the British 
Isles and 20,000 in the Un i ted States (1). Al though these 
figures are probably too high, it is clear that liver 
transplantation will be a common form of transplantation wi th 
numbers that may be competitive with the kidney. Realization of 
the objective of making liver transplantation a common service 
will depend upon the progress which I will be talking about 
today. 
HEPATIC REJECTION AND ITS PREVENTION 
Rejection of liver grafts is not different in principle than 
that which is seen with other transplanted organs. In untreated 
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dogs after 4 or 5 days, the typical findings include massive 
infiltration of mononuclear cells which are heavily concentrated 
around the portal tracts and central veins. Parenchymal necrosis 
and interstitial edema are other classical findings (1, 2): 
Almost two decades ago, the feasibili ty of hepatic 
t.ransplantation in patients with end stage liver disesase was 
established with the chronic survival of many dogs whose livers 
were replaced wi th grafts from non-related mongrel donors under 
trea tment with aza th i opr ine (1, 2). More than a dozen of the 
animals had therapy discontinued after about 4 months. Rejection 
did not supervene (1) and one of these dogs lived for more than a 
decade. The observation that therapy could often be stopped in 
these dogs as well as' later work in Paris, Bristol, Cambridge, 
and Denver with pigs suggested ttl'at the liver could be at the 
"easy" end of the scale .in terms of controlling rejection. That 
advantage, if it does exist, can be. easily overstated because 
rejection occurs frequently after human liver transplantation in 
spite of all efforts to prevent this process. 
The first extended survivals after human liver 
transplantation were obtained in the summer of 1967 (1). In 
January 1970 a child was treated who became the human counterpart 
of the canine exper iment in tha t her surv i val first equaled and 
·th en superc ed ed that of the famous dog. She is now 131;2 years 
post transplantation. I should say in passing that George Abouna 
was a member of the team that took care of this little girl. her 
treatment was with azathioprine, prednisone, and ALG. 
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INDICATIONS FOR LIVER TRANSPLANTATION 
The indications for liver transplantation in 237 consecutive 
cases are shown in Table 1. The heterogenous nature of the 
di'seases that can be treated' 
. 
is obvious. Chronic aggressive 
hepatitis, or more accurately non-alcoholic cirrhosis, was a 
leading indication, cutting across all age barriers. Biliary 
atresia was very common in pediatric patients. 
With all the indications in Table 1, we have tried to 
formula te some idea about the technical d i fficul ties that the 
surgeons can anticipate at the time of transplantation, the 
average degree of metabolic abnormali ties that can be expected 
L'om the original hepatic disease, the difficulties (if any) in 
deciding the propriety of candidacy, and finally the question of 
recurrence of the disease which had destroyed the" native liver. 
In Table 2 is a brief declaration of these issues in 
patients with biliary atresia. With this disorder, the decision 
about candidacy is a very easy one. Willis Potts, the great 
pediatric surgeon in Chicago, once wrote that biliary atresia had 
provided the blackest chapter in the history of pediatric 
surgery. His remarks were apt, since at that time nothing could 
be done for these children who required a major social, economic 
and medical input, but from whom nothing could be expected. The 
vic t ims of b i 1 iary a tres ia became par iahs as they entered the 
downh ill slope of the ir 1 i fe wi th the development of numerous 
secondary complications. The breakdown of parent-offspring 
relationships in ~hich the children became objects of despair and 
sometimes even hatred has been documented by social scientists. 
--~--~-- .. 
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Thus the decision to operate on a child with biliary atresia is 
an easy one. 
All patients with biliary atresia have had previous surgery, 
and this is an adverse factor, but not such a serious one as in 
adults. The most important technical problems with children with 
biliary atresia have come from associated anomalies, such as 
hypoplasia of the portal vein. The metabolic abnormali ties at 
the time of transplantation have ranged from minor to very 
severe, but usually they have not been unreasonable. In the past 
many of these children have died from the complications of 
biliary atresia while still possessing good synthetic functions 
of their liver. 
The same questions shown in Table 2 can be asked about all 
the major diseases for which transplantation might be 
indicated. Prospective recipients with non-alcoholic cirrhosis 
have been murderously difficult from a technical point of view 
and especially so when previous operations have been carried out 
with in the abdomen. The d eg ree of metabol ic decay has been 
unusually severe in such patients. 
active hepatitis who are B virus 
tendency to recapitulate in their 
Finally patients with chronic 
carriers have had a marked 
graft the same disease as 
destroyed their native liver. 
rate will be in the 80% range. 
It now appears that the recurrence 
Clearly, the full exploitation of 
liver replacement in such recipients will depend upon better ways 
of preventing a recurrence of the hepatitis. The use of 
hyperirr:mune spec i fic globul in, or the use of interferon are two 
possibilities. 
------------K-~~---
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The inborn errors of metabolism (Table 1) have provided for 
surgical scientists and for biochemists a unique opportunity. It 
was discovered almost two decades ago that a new liver provided 
new prote in phenotypes for the rec ip ient and that these donor 
specific phenotypes were retained for the life time of the 
graft-. This principle of donor specificity' of the liver 
homograft implies that hepatic based inborn errors of metabolism 
are curable by liver transplantation, and this implication has 
been proved on a number of occasions. The inborn errors shown in 
Table 1 (footnote) have all been metabolically "cured" wi th the 
poss i ble exception of the sea-blue h~stiocyte syndrome. Wi th 
congeni tal tyrosinemia and the glycogen storage diseases, there 
is a known and highly specific enzyme deficit in the livers; it 
has been shown that these enzymes when brought to the recipient 
with the new liver are thereafter present as long as the liver is 
viable. In other diseases such as Wilson's disease and alpha-1-
antitrypsin deficiency in which the exact enzyme deficit (if any) 
is not known, these disorders are also cured in spite of this 
ignorance about the·basic pathogenesis. 
Some of the most difficult decisions about candidacy have 
been in patients with hepatic malignancies (1, 3). The reason is 
that the incidence of recurrence in patients whose 'livers were 
replaced because primary tumors could not be removed wi th sub-
total resection have exhibi ted a very high inc idence of 
recurrence, more than 80% in our initial experience. In recent 
years, the inc idence of recurrence has been lower (3) but th is 
may only have reflected a better case selection. l1any of the 
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recipients with hepatic malignancies treated in the last several 
years have had the so called' fibrolamellar hepatomas which are 
late to metastasize, 
findings in livers 
or the hepatomas which occur as incidental 
destroyed by other diseases such as 
tyrosinemia, alpha-1-antitrypsin deficiency, and the seablue 
histiocyte syndrome. The role of liver replacement in the 
treatment of patients with otherwise nonresectable hepatic tumors 
has yet to be fully defined, but it is certain that the minority 
of patients would qualify. 
A number of diagnoses which are not well represented in 
Table 1 are certain to be more common in candidates for liver 
in the future. The most important of these transplantation 
diseases will be primary biliary cirrhosis and sclerosing 
The techhical ease with which liver replacement can 
out in primary biliary cirrhosis is remarkable. 
cholangitis. 
be carried 
Patients with this disorder have normal or sometimes larger than 
normal livers, with relatively modest portal hypertension, and 
wi th a disease evolution that is slow enough so that therapies 
can be carried out early before terminal deterioration of 
he a 1 t h . Th e d i a g nos i s 0 f scI e r 0 sin g c hoI an g i tis has a Ie s s 
favorable set of circumstances on the average since so many 
patients with this disease have either had total colectomy for 
the underlying disease of ulcerative colitis or else efforts at 
biliary tract reconstruction. 
TECHNICAL ASPECTS OF TRANSPLANTATION 
The preservation methods which can be used today are 
limited, but good enough to permit the harvesting of organs in 
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various parts of the United States with transfer of the hepatic 
gra fts for thousands of mi les. In Europe, s i m i lar network s have 
been set up leading to English, German and Dutch centers. 
The techniques of the actual transplantation have been so 
well described that there is Ii ttle point in discussing these 
here (1, 3). A recent development which is going to playa major 
role in permi tting transplantation to be used on a broad scale 
has been the use of veno-venous pump driven nonheparin 
bypasses. Wi th such bypasses, the blood from the occluded vena 
caval system as well as from the portal vein can be shunted 
around the upper abdomen during the period of obligatory venous 
obstruction and channeled into the axillary vein or some other 
vein of the upper half of the body. The physiologic stress 
imposed in the past during the so called anhepatic phase has been 
largely eliminated by this method which has been used for the 
last 20 or 25 adults. It is probable that the perfection of 
these nonheparin bypasses has been the most important technical 
development in almost 2 decades. 
In the early days of liver transplantation complications of 
biliary tract reconstruction were both frequent and lethal. 
These have been virtually eliminated in recent years. In our 
center the preferred form of biliary reconstruction is with duct 
to duct anastomosis over a T-tube. Obviously, this option does 
not exist for many ~atients (and by definition never with biliary 
atresia) but a very satisfactory alternative procedure is 
choledocojejunostorny using a Roux limb. 
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SURVIVAL 
With Conventional Immunosuppression (1963-1919) 
From 1963 to the end of 1919 110 consecutive patients were 
treated, an average case load of less than a dozen a year. 
Fifty-six (32.9%) of the recipients lived for at least one year 
and 32 (18.8%) are still alive with followups of 31;2 to 13112 
years. Six of the residual group are more than 10 years 
postoperative and 26 are more than 5 years. Only one patient who 
lived for as long as 5 years has subsequently died. 
The predominant mortality was in the first 3 postoperative 
months and was due mainly to technical surgical accidents, 
acceptance of some recipients with hopelessly advanced disease, 
the use of damaged liver grafts, the inability to control 
rejection, and a variety of infections. The major i ty of the 
deaths subsequent to this time were due to chronic rejection. 
With Cyclosporine-Steroid Therapy (1980-1981) 
Fourteen patients were treated in 1980 and 26 in 1981; 
fol.lowups of 18 to 38 months are available for those still 
living. The one year survival was 28/40 (10%). Three of the one 
year survivors died in the 13, 16, and 20th months of recurrent 
cholang iocarc inoma, recurr ing Budd-Ch iar i syndrome and chronic 
rejection (with an unsuccessful attempt at retransplantation) 
respectively. 
The Breakout Year of 1982 
In 1982, 2 important events occurred which demonstrated that 
1 i ver transp la nta t i on cou ld be explo i ted in many cen ters . For 
one thing, a large number of transplantations was carried out, 80 
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in all, an unprecedented number since the highest total in any 
prev ious year was only 30. In addition, fellows and residents 
began to do the operations, and contributed almost half of the 
cases. Dur i ng 1982-, half of the rec ip i ents have surv i ved wi ttl 
followups of 5 to 15 months. The losses still occurred 
perioperatively. 
The trials with the non-heparin bypass during the actual 
transplantation were begun late in our experience and the results 
in 1983 will have to be assessed before a final decision about 
the influence of this achievement will be forthcoming. 
In the meanwhile the movement of liver transplantation from 
an experimental to a service undertaking can be illustrated by 
studying the first 67 consecutive cases in what have been known 
as the cycl ospor i ne era. The compar i son . .of the resul ts using 
this drug with those in all previous experi~nce is shown in Table 
1. Resul ts ha ve been about tw i ce as good as in the past (Table 
1). 
Prospect for the Future 
The revitalization of interest in hepatic transplantation 
has dated from the better immunosuppression that became available 
31;2 years ago. Since that time the number of successful liver 
replacements has sharply increased. 
Forty-two patients have been followed for at least a year 
after Ii ver transplantation under cyclosporine-steroid therapy. 
The mystique surrounding liver transplantation has largely been 
dispelled during this time. Since 1980 other units in the United 
States and in other countries have been able to mount new and 
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effective programs. Thus liver transplantation has been 
deve loped to the po i nt of a serv ice opera t i on, the explo ita tion 
of which depends on the establishment of multiple regional 
centers. The increased "use of this procedure will permi t the 
delivery of optimal health care to victims of end stage liver 
disease. 
-- --- ~--~~ - ---
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Table 2. Factors of candidacy from experience 
with 237 consecutive patients. 
Biliary Atresia, 62 of the 237 cases 
Decision of Candidacy - - - - - - - - - -- - - Easy 
Previous Surgery - - - - - - - - - - 100% 
Metabolic Abnorrrali ties - - - - - - - - - - - - Hoderate 
* Technical Difficulties - - - - • - - - - - - - Moderate 
Disease Recurrence - - - - - - - - - - - - - - None 
* Unless there are anomalies 
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